H. Site-web-de-la, Haute Autorité de Santé [En ligne]. Fibrillation auriculaire, Juillet, 2007.

W. Aronow, C. Ahn, and H. Gutstein, Prevalence of Atrial Fibrillation and Association of Atrial Fibrillation with Prior and New Thromboembolic Stroke in Older Patients, Journal of the American Geriatrics Society, vol.323, issue.5, pp.521-524, 1996.
DOI : 10.1111/j.1532-5415.1996.tb01436.x

S. Stewart, C. Hart, and D. Hole, A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study, The American Journal of Medicine, vol.113, issue.5, pp.359-64, 2002.
DOI : 10.1016/S0002-9343(02)01236-6

E. Hylek, A. Go, and Y. Chang, Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation, New England Journal of Medicine, vol.349, issue.11, pp.1019-1045, 2003.
DOI : 10.1056/NEJMoa022913

R. Hart, O. Benavente, and R. Mcbride, Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation, Annals of Internal Medicine, vol.131, issue.7, pp.492-501, 1999.
DOI : 10.7326/0003-4819-131-7-199910050-00003

A. Investigators, S. Connoly, J. Pogue, and R. Hart, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, vol.367, pp.1903-1915, 2006.

A. Investigators, S. Connoly, J. Pogue, and R. Hart, Effect of clopidogrel added to aspirin in patients with atrial fibrillation, N Engl J Med, vol.360, pp.2066-78, 2009.

J. Mant, F. Hobbs, and K. Fletcher, Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, The Lancet, vol.370, issue.9586, pp.493-503, 2007.
DOI : 10.1016/S0140-6736(07)61233-1

S. Connolly, M. Ezekowitz, and Y. S. Re-ly, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009.
DOI : 10.1056/NEJMoa0905561

K. Mahaffey, Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarine in patients with non-valvular atrial fibrillation. Late-breaking clinical trail II. Congrès de l, American Heart Association, pp.13-17, 2010.

A. Camm, G. Lip, D. Caterina, and R. , 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation, Revista Espa??ola de Cardiolog??a (English Edition), vol.66, issue.1, pp.2719-2766, 2012.
DOI : 10.1016/j.rec.2012.11.003

G. Lip, R. Nieuwlaat, and R. Pisters, Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach, Chest, vol.137, issue.2, pp.263-72, 2010.
DOI : 10.1378/chest.09-1584

R. Pisters, D. Lane, R. Nieuwlaat, C. De-vos, H. Crijns et al., A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients

H. Site-web-de-la, Prise en charge des surdosages en antivitamines K, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier, Avril, 2008.

G. Palareti, N. Leali, and S. Coccheri, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT), The Lancet, vol.348, issue.9025, pp.423-431, 1996.
DOI : 10.1016/S0140-6736(96)01109-9

Y. Murray, R. Sacco, and W. Stevenson, HRS Guideline for the Management of Patients With Atrial Fibrillation : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 2014.

. Fibrillation-atriale-non-valvulaire, Quelle place pour les anticoagulants oraux non antivitamine K : apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®)

P. Wolf, R. Abbott, and W. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.983-991, 1991.
DOI : 10.1161/01.STR.22.8.983

C. Granger, J. Alexander, and J. Mcmurray, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), N Engl J Med, vol.365, pp.911-932, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00930087

R. Nieuwlaat, A. Capucci, and A. Camm, Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation, European Heart Journal, vol.26, issue.22, pp.2422-2456, 2005.
DOI : 10.1093/eurheartj/ehi505

W. Wattigney, G. Mensah, and J. Croft, Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention, ACC Current Journal Review, vol.13, issue.1, pp.711-717, 2003.
DOI : 10.1016/j.accreview.2003.10.016

B. Psaty, T. Manolio, and L. Kuller, Incidence of and Risk Factors for Atrial Fibrillation in Older Adults, Circulation, vol.96, issue.7, pp.2455-61, 1997.
DOI : 10.1161/01.CIR.96.7.2455

E. Benjamin, D. Levy, S. Vaziri, D. Agostino, R. Belanger et al., Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study, JAMA: The Journal of the American Medical Association, vol.271, issue.11
DOI : 10.1001/jama.271.11.840

G. Mitchell, R. Vasan, and M. Keyes, Pulse Pressure and Risk of New-Onset Atrial Fibrillation, JAMA, vol.297, issue.7, pp.709-724, 2007.
DOI : 10.1001/jama.297.7.709

T. Wang, M. Larson, and D. Levy, Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study, Circulation, vol.107, issue.23, pp.2920-2925, 2003.
DOI : 10.1161/01.CIR.0000072767.89944.6E

M. Komajda, O. Hanon, and M. Hochadel, Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I, European Heart Journal, vol.28, issue.11, pp.1310-1318, 2007.
DOI : 10.1093/eurheartj/ehl443

W. Kannel, P. Wolf, E. Benjamin, and D. Levy, Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available., The American Journal of Cardiology, vol.82, issue.7, pp.2-9, 1998.
DOI : 10.1016/S0002-9149(98)00583-9

N. Cohen, D. Almoznino-sarafian, and I. Alon, Warfarin for Stroke Prevention Still Underused in Atrial Fibrillation : Patterns of Omission, Stroke, vol.31, issue.6, pp.1217-1239, 2000.
DOI : 10.1161/01.STR.31.6.1217

R. Nieuwlaat, A. Capucci, and G. Lip, Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation, European Heart Journal, vol.27, issue.24, pp.3018-3044, 2006.
DOI : 10.1093/eurheartj/ehl015

E. Hylek, J. Antonio, and C. Evans-molina, Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation, Stroke, vol.37, issue.4, pp.1075-80, 2006.
DOI : 10.1161/01.STR.0000209239.71702.ce

C. Bilato, M. Corti, and G. Baggio, Prevalence, Functional Impact, and Mortality of Atrial Fibrillation in an Older Italian Population (from the Pro.V.A. Study), The American Journal of Cardiology, vol.104, issue.8, pp.1092-1099, 2009.
DOI : 10.1016/j.amjcard.2009.05.058

A. Ott, M. Breteler, M. De-bruyne, F. Van-harskamp, D. Grobbee et al., Atrial Fibrillation and Dementia in a Population-Based Study: The Rotterdam Study, Stroke, vol.28, issue.2, pp.316-337, 1997.
DOI : 10.1161/01.STR.28.2.316

S. Kalantarian, T. Stern, M. Mansour, and J. Ruskin, Cognitive Impairment Associated With Atrial Fibrillation, Annals of Internal Medicine, vol.158, issue.5_Part_1, pp.338-384, 2013.
DOI : 10.7326/0003-4819-158-5-201303050-00007

J. Eikelboom, O. Donnell, M. Yusuf, and S. , Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment, American Heart Journal, vol.159, issue.3, pp.348-53, 2010.
DOI : 10.1016/j.ahj.2009.08.026

G. Lip, L. Frison, J. Halperin, and D. Lane, Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.57, issue.2, pp.173-80, 2011.
DOI : 10.1016/j.jacc.2010.09.024

G. Pernod, P. Albaladejo, and A. Godier, Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct